About Qiagen
Qiagen is a company based in Hilden (Germany) founded in 1984 by Metin Colpan and Jurgen Schumacher was acquired by Thermo Fisher Scientific in March 2020.. The company has 5,760 employees as of December 31, 2024. Qiagen has completed 25 acquisitions, including AmniSure, Artus Biotech and Blirt. Qiagen offers products and services including QIAcuityDx, QIAwave Kits, Proteinase K, and TissueLyser III. Qiagen operates in a competitive market with competitors including ArcherDX, Parse Biosciences, Biofidelity, RareCyte and RainDance, among others.
- Headquarter Hilden, Germany
- Employees 5760 as on 31 Dec, 2024
- Founders Metin Colpan, Jurgen Schumacher
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Qiagen India Private Limited
- Date of Incorporation 11 Dec, 2009
- Jurisdiction New Delhi, Delhi, India
-
Annual Revenue
$1.98 B0.66as on Dec 31, 2024
-
Net Profit
$83.59 M-75.51as on Dec 31, 2024
-
EBITDA
$698.23 M7.32as on Dec 31, 2024
-
Latest Funding Round
$60.64 K (USD), Grant
Jan 20, 2022
-
Investors
Thermo Fisher Scientific
& 3 more
-
Employee Count
5760
as on Dec 31, 2024
-
Investments & Acquisitions
AmniSure
& 24 more
-
Acquired by
Thermo Fisher Scientific
(Mar 03, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Qiagen
Qiagen is a publicly listed company on the NYSE with ticker symbol QGEN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Qiagen
Qiagen offers a comprehensive portfolio of products and services, including QIAcuityDx, QIAwave Kits, Proteinase K, and TissueLyser III. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Fully automated system for accurate genetic variation detection and quantification
Eco-friendly kits for efficient DNA and RNA sample processing
Enzyme for protein digestion in biological sample preparation
Instrument for effective lysis of challenging biological samples
Unlock access to complete
Unlock access to complete
Software Development Team
67 people
Leadership Team
56 people
Sales and Marketing
55 people
Senior Team
47 people
Human Resources and Administration
29 people
Operations Team
17 people
Product Management Team
16 people
Field Team
14 people
Unlock access to complete
Funding Insights of Qiagen
- Total Funding Total Funding
- Total Rounds 13
- Last Round Grant — $60,643
-
First Round
First Round
(02 Oct 2007)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2022 | Amount | Grant - Qiagen | Valuation |
investors |
|
| Jul, 2021 | Amount | Grant - Qiagen | Valuation |
investors |
|
| Mar, 2021 | Amount | Grant - Qiagen | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Qiagen
Qiagen has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include Thermo Fisher Scientific, HHS and European Union. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location | |
|
Administers health care and support for military personnel and operations.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Qiagen
Qiagen has strategically engaged in corporate development activities, having acquired 25 companies. Notable acquisitions include AmniSure, Artus Biotech and Blirt. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Diagnostic decision support solution for radiologists
|
2017 | ||||
|
A DNA sequencing platform for forensic science applications is developed.
|
2017 | ||||
|
Genomic data is stored and managed through a cloud-based platform.
|
2012 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Qiagen
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Qiagen Comparisons
Competitors of Qiagen
Qiagen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ArcherDX, Parse Biosciences, Biofidelity, RareCyte and RainDance, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| domain | founded_year | HQ Location |
RNA-sequencing transcriptome kits for health data analysis are developed.
|
|
| domain | founded_year | HQ Location |
Molecular diagnostic assays are developed for target DNA sequence detection.
|
|
| domain | founded_year | HQ Location |
Developer of technologies for the analysis of rare and single cells in the blood
|
|
| domain | founded_year | HQ Location |
Developer of nucleic acid detection and quantification systems
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Qiagen
Frequently Asked Questions about Qiagen
When was Qiagen founded?
Qiagen was founded in 1984 and raised its 1st funding round 23 years after it was founded.
Where is Qiagen located?
Qiagen is headquartered in Hilden, Germany. It is registered at Hilden, North Rhine-westphalia, Germany.
Who is the current CEO of Qiagen?
Metin Colpan is the current CEO of Qiagen. They have also founded this company.
How many employees does Qiagen have?
As of Dec 31, 2024, the latest employee count at Qiagen is 5,760.
What is the annual revenue of Qiagen?
Annual revenue of Qiagen is $1.98B as on Dec 31, 2024.
What does Qiagen do?
Qiagen was founded in 1984 in Hilden, Germany, and operates in the biotechnology sector. Molecular diagnostic assays are supported through products that isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. Reagents for PCR, sequencing, detection, automated systems, analytics software, RNAi, epigenetics, and laboratory essentials are provided to research and clinical applications worldwide.
Who are the top competitors of Qiagen?
Qiagen's top competitors include Parse Biosciences, ArcherDX and NuProbe.
What products or services does Qiagen offer?
Qiagen offers QIAcuityDx, QIAwave Kits, Proteinase K, and TissueLyser III.
Is Qiagen publicly traded?
Yes, Qiagen is publicly traded on NYSE under the ticker symbol QGEN.
How many acquisitions has Qiagen made?
Qiagen has made 25 acquisitions, including AmniSure, Artus Biotech, and Blirt.
Who are Qiagen's investors?
Qiagen has 4 investors. Key investors include Thermo Fisher Scientific, HHS, European Union, and Military Health.
What is Qiagen's ticker symbol?
The ticker symbol of Qiagen is QGEN on NYSE.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.